/ACOGF

ACOGF Stock - Alpha Cognition Inc.

Q: What is the analyst price target for ACOGF?

Analyst price target information is not currently available for ACOGF.

Q: What is ACOGF's market cap?

Market capitalization information is not currently available for ACOGF.

Healthcare|Biotechnology|OTC

$5.72+0.00%

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+214.4%upside

Target: $18.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ACOGF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.29

52W High$5.72

52W Low$5.72

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-86,028	$-87,320	$-89,086	$-85,746	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-9,705,601	$-13,463,699	$-11,566,654	$-5,682,590	$-5,161,052
Net Income	$-13,772,567	$-12,114,698	$-19,545,016	$-5,784,207	$-6,606,527
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.15	$-0.18	$-0.37	$-0.96	$-0.21

Company Overview

Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Visit Website

Earnings History & Surprises

ACOGF

Beat Rate

17%

Last 6 quarters

Avg Surprise

-134.9%

EPS vs Estimate

Beats / Misses

1/4

1 met exactly

Latest EPS

$-0.31

Q4 2024

EPS Surprise History

Q1 23

-66.7%

$-0.05vs$-0.03

Q2 23

No data

Q3 23

No data

Q4 23

No data

Q2 24

No data

Q2 24

No data

Q3 24

-75.1%

$-0.01vs$-0.01

Q4 24

-671.1%

$-0.31vs$-0.04

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2024	Nov 26, 2024	$-0.04	$-0.31	-671.1%	✗ MISS
Q3 2024	Aug 12, 2024	$-0.01	$-0.01	-75.1%	✗ MISS
Q2 2024	May 14, 2024	—	$-0.03	—	—
Q2 2024	Apr 3, 2024	—	$-0.02	—	—
Q4 2023	Nov 28, 2023	—	$-0.03	—	—
Q3 2023	Aug 22, 2023	—	$-0.03	—	—
Q2 2023	May 30, 2023	—	$-0.02	—	—
Q1 2023	Mar 8, 2023	$-0.03	$-0.05	-66.7%	✗ MISS
Q4 2022	Nov 28, 2022	$-0.05	$-0.04	+20.0%	✓ BEAT
Q3 2022	Aug 25, 2022	$-0.05	$-0.05	0.0%	= MET
Q2 2022	May 31, 2022	—	$-0.04	—	—
Q2 2022	Apr 28, 2022	$-0.06	$-0.07	-16.7%	✗ MISS
Q4 2021	Nov 27, 2021	—	$-0.08	—	—
Q3 2021	Aug 30, 2021	—	$0.00	—	—
Q2 2021	May 31, 2021	—	$-0.28	—	—
Q2 2021	May 28, 2021	—	$-0.54	—	—
Q4 2020	Oct 31, 2020	—	$-0.05	—	—
Q4 2019	Dec 31, 2019	—	$-0.00	—	—
Q4 2019	Oct 31, 2019	—	$-0.01	—	—